Shruti Abbato Principal, Perspicere, LLC Shruti Abbato is a Principal at Perspicere LLC, an advisory business focused on providing transaction and strategy related support to life science companies. Prior to Perspicere, Ms. Abbato was Director of Business Development at Human Genome Sciences, Inc. (HGS), a public biopharmaceutical company, acquired by GlaxoSmithKline (GSK) in July 2012. Ms. Abbato joined HGS in 2000 and was responsible for search and evaluation, in- and out-licensing transactions, and merger and acquisition activities for broadening HGS' pipeline of therapeutic products and portfolio of enabling antibody and protein technologies. She has a depth of experience in strategic, financial, and commercial assessments, and in negotiating term sheets and contracts for a broad range of transactions. She has led numerous transaction processes and established multiple partnerships for HGS with biopharmaceutical and pharmaceutical companies. In addition, Ms. Abbato was a member of the deal team for HGS' sale process (and subsequent acquisition by GSK) and was responsible for sale related due diligence activities. Following the acquisition of HGS and through February 2013, Ms. Abbato was co-founder of and responsible for venture financing activities for a spin-off of HGS’ research division. Ms. Abbato started her career in life sciences in 1995 and was at Merck & Co. and then at North American Vaccine, Inc., until 1999, where she held process engineering roles of increasing responsibilities for the development and production of biologics. She has an M.B.A. from the University of Pittsburg's Katz School of Business with a concentration in Finance. She also holds Bachelor's degrees in Chemical Engineering and in Biochemistry from the University of Maryland at College Park.
Shruti Abbato Principal, Perspicere, LLC Shruti Abbato is a Principal at Perspicere LLC, an advisory business focused on providing transaction and strategy related support to life science companies. Prior to Perspicere, Ms. Abbato was Director of Business Development at Human Genome Sciences, Inc. (HGS), a public biopharmaceutical company, acquired by GlaxoSmithKline (GSK) in July 2012. Ms. Abbato joined HGS in 2000 and was responsible for search and evaluation, in- and out-licensing transactions, and merger and acquisition activities for broadening HGS' pipeline of therapeutic products and portfolio of enabling antibody and protein technologies. She has a depth of experience in strategic, financial, and commercial assessments, and in negotiating term sheets and contracts for a broad range of transactions. She has led numerous transaction processes and established multiple partnerships for HGS with biopharmaceutical and pharmaceutical companies. In addition, Ms. Abbato was a member of the deal team for HGS' sale process (and subsequent acquisition by GSK) and was responsible for sale related due diligence activities. Following the acquisition of HGS and through February 2013, Ms. Abbato was co-founder of and responsible for venture financing activities for a spin-off of HGS’ research division. Ms. Abbato started her career in life sciences in 1995 and was at Merck & Co. and then at North American Vaccine, Inc., until 1999, where she held process engineering roles of increasing responsibilities for the development and production of biologics. She has an M.B.A. from the University of Pittsburg's Katz School of Business with a concentration in Finance. She also holds Bachelor's degrees in Chemical Engineering and in Biochemistry from the University of Maryland at College Park.
Shruti%20Abbato%20Bio.docx